Psilocybin therapy helps clinicians process COVID despair
Peer-Reviewed Publication
Updates every hour. Last Updated: 19-Apr-2025 13:08 ET (19-Apr-2025 17:08 GMT/UTC)
Psilocybin-assisted psychotherapy resulted in significant reductions in depression among clinicians who provided front-line COVID-19 care in 2020 and 2021. These reductions were measurably greater than those experienced by the cohort of clinicians who received a placebo instead. Findings from this double-blind, randomized clinical trial are to be published in JAMA Network Open at 8 a.m. PST Thursday, Dec. 5.
“For doctors and nurses who feel burned out or disillusioned or disconnected from the patient care they want to provide, this study shows that psilocybin therapy is safe and can help these clinicians work through those feelings and get better,” said Dr. Anthony Back, the lead investigator.
Dartmouth researchers use game theory to propose a new way of thinking about masking and social distancing rules that is more responsive to public sentiment and may help increase cooperation. The study is the first to consider mask wearing and social distancing as competing actions that people respond to differently, which would give public health officials more flexibility to adapt to epidemics.
Most young people who were confirmed to have long Covid three months after a positive PCR test had recovered within 24 months, finds a new study led by UCL researchers.
McGill University scientists have discovered that pregnancy may trigger a natural immunity to boost protection against severe flu infection. Contrary to the common belief that pregnancy increases vulnerability to infections, researchers found that it strengthened an immune defense in mice, blocking the Influenza A virus from spreading to the lungs, where it can cause severe infection.
Kumamoto University researchers have identified a powerful antibody that can neutralize a wide range of SARS-CoV-2 variants, including the elusive Omicron subvariants.
Researchers from Helmholtz Munich and Ludwig-Maximilians-Universität (LMU) have identified a mechanism that may explain the neurological symptoms of Long COVID. The study shows that the SARS-CoV-2 spike protein remains in the brain’s protective layers, the meninges, and the skull’s bone marrow for up to four years after infection. This persistent presence of the spike protein could trigger chronic inflammation in affected individuals and increase the risk of neurodegenerative diseases. The team, led by Prof. Ali Ertürk, Director at the Institute for Intelligent Biotechnologies at Helmholtz Munich, also found that mRNA COVID-19 vaccines significantly reduce the accumulation of the spike protein in the brain. However, the persistence of spike protein after infection in the skull and meninges offers a target for new therapeutic strategies.